February 2023 in “Journal of plant science and phytopathology” Jatropha dioica may have antiviral, antifungal, and other medicinal properties, but more research is needed.
2 citations
,
August 2017 in “Drug and therapeutics bulletin” Strontium ranelate is no longer available for treatment.
52 citations
,
July 1998 in “Urology” Liarozole may be more effective than cyproterone acetate for treating advanced prostate cancer, with better PSA response and survival rates, while maintaining quality of life.
34 citations
,
July 2011 in “International journal of pharmaceutics” Ion-paired risedronate significantly increases skin penetration without irritation compared to risedronate alone.
September 2024 in “Drugs & Therapy Perspectives” Ritlecitinib effectively regrows hair in severe alopecia areata and is well tolerated.
July 2024 in “Reactions Weekly” March 2023 in “Reactions Weekly” 16 citations
,
April 2006 in “Pediatrics International” High-dose mizoribine effectively controls symptoms in adolescents with lupus while reducing steroid use, with manageable side effects.
7 citations
,
October 2024 in “Journal of the American Academy of Dermatology” Continued ritlecitinib treatment helps sustain hair regrowth in alopecia areata patients.
March 2023 in “SKIN The Journal of Cutaneous Medicine” Ritlecitinib helped most alopecia areata patients regrow hair by Week 48.
39 citations
,
January 1977 in “Dermatology” The treatment cleared psoriasis in some patients but caused side effects in most.
20 citations
,
September 1983 in “Archives of dermatology” The new synthetic retinoid RO 13-6298 effectively treated severe psoriasis at low doses with manageable side effects.
April 2023 in “The journal of investigative dermatology/Journal of investigative dermatology” Ritlecitinib significantly improves scalp hair regrowth in alopecia areata patients over time.
12 citations
,
October 1978 in “PubMed” Ro 10-9359 is an effective treatment for severe psoriasis but can cause side effects.
February 2023 in “Reactions Weekly”
84 citations
,
August 2023 in “Drugs” Ritlecitinib is approved in the USA and Japan for treating severe hair loss in people aged 12 and older.
September 2023 in “Medicina Estética Revista Científica de la Sociedad Española de Medicina Estética (SEME)” The FDA approved Litfulo® for treating severe alopecia areata in people aged 12 and older.
May 2024 in “Reactions weekly” June 2026 in “British Journal of Dermatology” Ritlecitinib shows promise in improving severe alopecia areata, with 27% of patients seeing success.
July 2023 in “SKIN The Journal of Cutaneous Medicine” Continued ritlecitinib treatment can improve hair regrowth in some alopecia areata patients who initially don't respond.
July 2025 in “Journal of Investigative Dermatology” Solid Lipid Particle technology makes retinol more stable, effective, and gentle on the skin.
2 citations
,
June 2024 in “Dermatology” Ritlecitinib improves hair regrowth satisfaction in alopecia areata patients.
November 2025 in “SKIN The Journal of Cutaneous Medicine” Ritlecitinib is effective long-term for treating alopecia areata in teens.
October 2025 in “Dermatology and Therapy” Ritlecitinib is being tested for effectiveness and safety in treating severe alopecia areata.
July 2026 in “Journal of the American Academy of Dermatology” Ritlecitinib helps adolescents with severe alopecia areata regrow scalp hair and normalize body hair and nails.
1 citations
,
March 2026 in “American Journal of Clinical Dermatology” Ritlecitinib effectively regrows hair in severe alopecia areata, especially in adolescents.
September 2024 in “Annals of Medicine and Surgery” Ritlecitinib is the first FDA-approved pill for treating significant hair loss in alopecia areata patients aged 12 and up.